Clinical trials: Stage IV Adenocarcinoma of the Gastroesophageal Junction
Esophageal Cancer
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as cetuximab may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00096031
- Testing
- cetuximab
- Where
- 152 sites in United States
- Volunteers
- 63 people
- Sponsor
- SWOG Cancer Research Network
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places…
- Conditions
- Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03641313
- Testing
- Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy
- Where
- 31 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT01939275
- Testing
- copper Cu 64-DOTA-trastuzumab, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00732745
- Testing
- docetaxel, oxaliplatin, vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
This randomized phase II trial studies combination chemotherapy when given together with vismodegib to see how well it works compared with combination chemotherapy without vismodegib in treating patients with advanced stomach…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer
- Trial name
- NCT00982592
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05677490
- Testing
- Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Where
- 802 sites in United States, Puerto Rico
- Volunteers
- 382 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00891878
- Testing
- capecitabine, sunitinib malate
- Where
- 182 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophageal Cancer, Gastric Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with surgery is more effective than surgery alone.
- Trial name
- NCT00002883
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- France
- Volunteers
- 250 people
- Sponsor
- UNICANCER
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Gastric Adenocarcinoma, Stage II Gastric Cancer
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction.
- Conditions
- Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
- Trial name
- NCT00062374
- Testing
- Cisplatin, Computed Tomography, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan (ABBV-400) is…
- Conditions
- Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- AndroMETa-GEA (NCT06628310)
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Fluorouracil
- Where
- 49 sites in United States, Belgium and 9 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of Akt inhibitor MK2206 and lapatinib ditosylate when given together with trastuzumab in treating patients with locally advanced or metastatic human epidermal growth…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01705340
- Testing
- Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
- Trial name
- NCT07556640
- Testing
- LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other…
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma
- Trial name
- NCT03008278
- Testing
- Olaparib, Ramucirumab
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
This phase II trial is studying how well bortezomib with or without irinotecan works in treating patients with gastroesophageal junction or stomach cancer that can not be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00061932
- Testing
- bortezomib, irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have unresectable or…
- Trial name
- NCT00074009
- Testing
- bortezomib
- Where
- 4 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach
- Trial name
- NCT02830594
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04007744
- Testing
- Pembrolizumab, Sonidegib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic